# Phase 5.2.3 Sub-Milestone 4.4.1: REQ-44 Final Implementation Report
**Document ID**: `phase523_milestone44_1_req44_implementation_report.md`  
**Phase**: ClinicalDoc Phase 5.2.3 — Sub-Milestone 4.4.1  
**Status**: COMPLETE / VERIFIED  
**Date**: October 31, 2026  
**Auditor / Implementer**: Autonomous Pair Programming Agent (Antigravity)  
**Authorized Scope**: Strict two-file implementation boundary (`src/clindoc/fhir/mapper.py` and `tests/test_phase523_milestone4_4.py`)  

---

## 1. Executive Summary & Authorization Reconciliation

Following the completion and review of:
1. `phase523_milestone44_req44_remediation_design_review_v3_1.md`
2. `REQ44_IMPLEMENTATION_READINESS_ASSESSMENT.md`

Sub-Milestone 4.4.1 was authorized to reconcile production code conflicts and finalize the implementation of **REQ-44 (Medication Regimen Partitioning, Durations, and Lifecycle Mapping)** under strict boundaries.

All objectives have been fully implemented, verified, and regression-tested:
- **Clarification 1 (FHIR Lifecycle Mapping)**: Decoupled prescription cancellation from patient cessation. Historical medication mentions route exclusively to `MedicationStatement(status="unknown")` with `EXT_TEMPORAL_STATUS` (`code="historical"`) and never fabricate a `MedicationRequest`. Unreferenced cancellations fail closed (suppressed via audit trail). Completed courses require direct syntactic linkage, rejecting detached non-medication completions.
- **Clarification 2 (Mandatory Test Inventory)**: Built and verified a complete 19-test suite in `tests/test_phase523_milestone4_4.py` (7 baseline + 12 comprehensive new edge-case tests), achieving 100% pass rate.
- **Clarification 3 (Verbatim Narrative SIG Preservation)**: Preserved source phrasing across all clauses, normalizing drug name prefixes while strictly stripping non-medication clinical sentences (follow-up appointments, monitoring orders, symptom histories) without loss of transition cues or duration context.
- **Boundary Invariants**: Zero modifications to `src/clindoc/review/service.py` and `src/clindoc/services/fhir_export.py`. The multi-hop Four-Eyes ancestry vulnerability remains an absolute clinical export blocker at Gate 9. Zero Git commands executed. Standard FHIR R4B conformance strictly maintained.
- **Verification Integrity**: Full test suite passed with 1,466 passing tests (1,454 baseline + 12 new tests) and exactly the 5 pre-existing known failures, with 0 regressions and 0 denominator drift across the 12-doc and 60-doc benchmark cascades.

---

## 2. Resolution of the Final Three Clarifications

### 2.1 Clarification 1: FHIR Lifecycle Mapping & Decoupling

| Scenario / Intent | Prior Conflict / Ambiguity | Implemented REQ-44 Behavior | Enforcing Mechanism |
| :--- | :--- | :--- | :--- |
| **Historical Medication Mention** | Previously routed to `MedicationRequest(status="completed")` if found on Rx pad, fabricating an ungrounded order. | Routes **strictly** to `MedicationStatement(status="unknown")`, accompanied by `EXT_TEMPORAL_STATUS` extension (`valueCode="historical"`). `MedicationRequest` is **never** emitted. | `claims_to_fhir_bundle` lifecycle router: `if temp_status == "historical": is_request = False; stat_status_override = "unknown"` |
| **Unreferenced Order Cancellation** | Ambiguous instruction in clinic notes ("Discontinue Lisinopril 20 mg") risked fabricating either `MedicationRequest(status="cancelled")` without an order reference or `MedicationStatement(status="stopped")` without cessation evidence. | **Fails closed**. Requires both a verifiable prior order reference (`ORDER_REF_REGEX`) and explicit cancellation command (`ORDER_CANCEL_REGEX`). Without both, the medication resource is suppressed and logged to the audit trail as `UNREFERENCED_ORDER_CANCELLATION_FAIL_CLOSED`. | `claims_to_fhir_bundle` check: `if not (ORDER_REF_REGEX.search(...) and ORDER_CANCEL_REGEX.search(...)): continue` (suppressed) |
| **Patient-Reported Cessation** | Previously conflated with order cancellation. | Emits `MedicationStatement(status="stopped")` **only** when supported by independent evidence of actual patient cessation (`PATIENT_CESSATION_REGEX`). | `PATIENT_CESSATION_REGEX.search(med_grp_full_text)` -> `is_request = False; stat_status_override = "stopped"` |
| **Completed Course Linkage** | Detached non-medication completions ("Patient completed physical therapy course") leaked into medication resources. | Explicitly completed therapy may emit `MedicationStatement(status="completed")` only when directly linked to the medication course. Non-medication targets (`DETACHED_COMPLETION_TARGET_REGEX`) are detached and prevented from marking medications completed. | `COMPLETED_COURSE_REGEX.search(...) and not DETACHED_COMPLETION_TARGET_REGEX.search(...)` |

### 2.2 Clarification 2: Mandatory Test Inventory Coverage

All 19 tests in `tests/test_phase523_milestone4_4.py` are executed and passing:

| # | Test Name | Target Requirement | Input Narrative / Scenario | Assertion & Outcome | Status |
| :---: | :--- | :--- | :--- | :--- | :---: |
| 1 | `test_w2_multipage_medication_split_fail_closed` | REQ-44-01 | Page 1 drug name, Page 2 continuation dose in `__no_anchor__`. | Page 2 dose strictly isolated, no orphan emission. | **PASSED** |
| 2 | `test_req_44_03_shared_evidence_duplicate_duration_matching` | REQ-44-03 | "40 mg daily for 2 weeks, then 20 mg daily for 2 weeks, then 10 mg daily" | Occurrence tie-breaking assigns 2 wk to P1, 2 wk to P2, P3 unbounded. | **PASSED** |
| 3 | `test_req_44_04_narrative_sig_transition_context_sufficiency` | REQ-44-04 | "Prednisone: 20 mg daily for 5 days, then 10 mg daily for 5 days, then 5 mg daily." | P1: "Prednisone 20 mg daily for 5 days", P2: "Then 10 mg daily for 5 days", P3: "Then 5 mg daily". Zero dose summation. | **PASSED** |
| 4 | `test_split_dosing_e2e_bundle_and_fhir_validator` | REQ-44-02 | "Carvedilol 12.5 mg every morning and 25 mg at bedtime." | Concurrent dosages sharing sequence=1; FHIRValidator valid. | **PASSED** |
| 5 | `test_sequential_taper_medication_statement_e2e_validator` | REQ-44-02 | "Methylprednisolone 16 mg daily for 3 days, then 8 mg daily." | Progress note maps to MedicationStatement; P1 bounded, P2 open. | **PASSED** |
| 6 | `test_competing_candidate_shadowing_provenance_emitted` | REQ-44-05 | Competing dose extractions (6.25 mg vs 6.250 mg). | Winning candidate selected; competing candidate shadowed in extension. | **PASSED** |
| 7 | `test_four_eyes_ancestry_blocker_remains_active` | Gate 9 Safety | In-memory accepted claim evaluated by FHIRExportService. | Suppressed with `SUPPRESSED_UNVERIFIED_AUDIT_LEDGER`. | **PASSED** |
| 8 | `test_req44_leading_duration` | REQ-44-02 | "For 2 weeks take 40 mg daily, then for 2 weeks take 20 mg daily, then take 10 mg daily." | P1: boundsDuration 2 wk; P2: boundsDuration 2 wk; P3: open-ended. | **PASSED** |
| 9 | `test_req44_mixed_duration_placement` | REQ-44-02 | "40 mg daily for 2 weeks, then for 2 weeks take 20 mg daily, then 10 mg daily." | Trailing duration in P1 and leading duration in P2 both bind correctly. | **PASSED** |
| 10 | `test_req44_duration_vs_followup_review_interval` | REQ-44 Semantic Roles | "Prednisone 40 mg daily for 2 weeks, then 60 mg daily. Review after 1 week." | "1 week" classified as `ROLE_FOLLOWUP_REVIEW`; P2 has boundsDuration=None. | **PASSED** |
| 11 | `test_req44_duration_vs_monitoring_reassessment` | REQ-44 Semantic Roles | "Prednisone 40 mg daily for 2 weeks, then 20 mg daily. Repeat labs in 5 days." | "5 days" classified as `ROLE_MONITORING_REASSESSMENT`; omitted from dosage. | **PASSED** |
| 12 | `test_req44_paragraph_break_without_transition_fails_closed` | REQ-44 Rule 2 | "Prednisone 40 mg daily for 2 weeks.\n\nTake 20 mg daily for 2 weeks." | Paragraph break without explicit transition token fails closed against taper merging. | **PASSED** |
| 13 | `test_req44_ocr_line_wrap_with_explicit_transition` | REQ-44 Rule 2 | "Prednisone 40 mg daily for 2 weeks,\nthen 20 mg daily for 2 weeks." | Soft newline with "then" successfully synthesizes 2-phase taper. | **PASSED** |
| 14 | `test_req44_taxonomy_case_b_multiple_regimen_durations` | REQ-44 Taxonomy B | "Prednisone 40 mg daily for 2 weeks for 3 days." | Conflicting regimen durations fail closed (`AMBIGUOUS_MULTI_DURATION_CONFLICT`). | **PASSED** |
| 15 | `test_req44_taxonomy_case_d_symptom_history_duration` | REQ-44 Taxonomy D | "Lisinopril 10 mg daily. Patient reports back pain with symptom duration 6 months." | "6 months" classified as `ROLE_NON_MED_CLINICAL_HISTORY`; omitted from med. | **PASSED** |
| 16 | `test_req44_lifecycle_unreferenced_cancellation_fails_closed` | REQ-44 Lifecycle | "Discontinue Lisinopril 20 mg." (no order ref, no patient cessation) | Fails closed: no MedicationRequest or MedicationStatement emitted. | **PASSED** |
| 17 | `test_req44_lifecycle_patient_cessation_emits_stopped` | REQ-44 Lifecycle | "Patient stopped taking Lisinopril 20 mg daily due to dry cough." | Emits `MedicationStatement(status="stopped")`. | **PASSED** |
| 18 | `test_req44_lifecycle_historical_maps_to_unknown_not_completed` | REQ-44 Lifecycle | "History of Prednisone 20 mg daily in 2023." | Emits `MedicationStatement(status="unknown")` with temporal extension. | **PASSED** |
| 19 | `test_req44_lifecycle_completed_requires_syntactic_linkage` | REQ-44 Lifecycle | "Amoxicillin 500 mg tid for 10 days. Patient completed physical therapy course." | Completion of physical therapy does NOT mark Amoxicillin completed (`status="active"`). | **PASSED** |

### 2.3 Clarification 3: Verbatim Source Narrative Preservation

The narrative text of each dosage instruction (`Dosage.text`) is constructed directly from the corresponding partitioned source span:
1. **Clause Span Extraction**: Slices `full_grp_text[l_k:r_k]` based on transition boundaries $[L_k, R_k)$.
2. **Non-Medication Sentence Stripping**: Strips downstream non-medication follow-up sentences (e.g. `Review after 1 week`, `Repeat labs in 5 days`, `Symptom duration 6 months`) using regex lookahead bounded by sentence boundaries (`.`, `\n`).
3. **Prefix Normalization**: Strips colon notation (`Prednisone: 20 mg` -> `Prednisone 20 mg`).
4. **Transition Continuity**: Prepends `"Then "` to subsequent phases if not already capitalized in the text, preserving human MAR readability.
5. **Zero Distortion**: Prohibits cross-phase dose summation (e.g., Phase 1 `20 mg` + Phase 2 `10 mg` + Phase 3 `5 mg` is never reported as `35 mg`).

---

## 3. Code Modification Boundary Audit

### 3.1 Authorized Files Modified

Strictly two authorized files were modified in accordance with the Sub-Milestone 4.4.1 mandate:

1. `src/clindoc/fhir/mapper.py`:
   - Added semantic role regexes (`ROLE_FOLLOWUP_REGEX`, `ROLE_MONITORING_REGEX`, `ROLE_NON_MED_HISTORY_REGEX`).
   - Added order lifecycle regexes (`ORDER_REF_REGEX`, `ORDER_CANCEL_REGEX`, `PATIENT_CESSATION_REGEX`, `COMPLETED_COURSE_REGEX`, `DETACHED_COMPLETION_TARGET_REGEX`).
   - Implemented `_classify_temporal_role` with sentence-bounded local windows.
   - Updated `_build_regimen_dosages` with transition-grounded $[L_k, R_k)$ partitioning, Rule 2 paragraph fail-closed enforcement, Case B ambiguous duration fail-closed handling, and narrative sentence preservation.
   - Added `status_override` to `map_medication_request` and `map_medication_statement`.
   - Wired `enforce_req44_lifecycle` parameter and lifecycle gating logic into `claims_to_fhir_bundle`.
2. `tests/test_phase523_milestone4_4.py`:
   - Added 12 new comprehensive test cases covering all edge cases, taxonomies, and lifecycle rules.

### 3.2 Strict Code Freeze & Gate 9 Verification

- `src/clindoc/review/service.py`: **UNTOUCHED** (0 bytes changed).
- `src/clindoc/services/fhir_export.py`: **UNTOUCHED** (0 bytes changed).
- **Four-Eyes Ancestry Vulnerability**: Test `test_four_eyes_ancestry_blocker_remains_active` passed. Any claim lacking a verified audit ledger entry continues to fail closed with `SUPPRESSED_UNVERIFIED_AUDIT_LEDGER`. Multi-hop provenance cannot bypass export safety.
- **Git State**: Zero Git operations executed (no stage, commit, push, stash, checkout, or reset).
- **FHIR Schema**: Pure FHIR R4B standard resources (`MedicationRequest`, `MedicationStatement`, `Timing`, `Duration`, `Extension`). Zero proprietary or non-standard FHIR structures.

---

## 4. Verification & Regression Analysis

### 4.1 Full Repository Test Suite

```text
=========================== short test summary info ===========================
FAILED tests/test_cli.py::test_cli_unsupported_extension_fails - assert 0 == 1
FAILED tests/test_document_ingestion.py::test_13_unreadable_invalid_document_handling
FAILED tests/test_m2_v2_corrections.py::test_lab_flag_v2_generation - AssertionError
FAILED tests/test_section_detection_production.py::TestSectionDetectionDisabledParity::test_disabled_mode_extracts_headers_identically_to_baseline
FAILED tests/test_vllm_deployment.py::test_client_code_does_not_disable_tls_verification
=================== 5 failed, 1466 passed, 11 warnings in 282.12s ===================
```

- **Baseline passing tests**: 1,454
- **New passing tests**: +12
- **Current passing tests**: 1,466
- **Failures**: Exactly the 5 pre-existing known failures. Zero new failures. Zero regressions.

### 4.2 Benchmark Integrity

Execution of `external_eval/tests/test_synthetic_benchmark.py` and `external_eval/tests/test_expanded_benchmark.py`:
```text
external_eval/tests/test_synthetic_benchmark.py::test_manifest_structure_and_document_counts PASSED [ 12%]
external_eval/tests/test_synthetic_benchmark.py::test_verbatim_text_slicing_on_synthetic_notes PASSED [ 25%]
external_eval/tests/test_synthetic_benchmark.py::test_zero_mock_qwen_detection PASSED [ 37%]
external_eval/tests/test_synthetic_benchmark.py::test_deterministic_evaluation_reproducibility PASSED [ 50%]
external_eval/tests/test_expanded_benchmark.py::test_expanded_manifest_structure PASSED [ 62%]
external_eval/tests/test_expanded_benchmark.py::test_verbatim_text_slicing_all_60_documents PASSED [ 75%]
external_eval/tests/test_expanded_benchmark.py::test_all_10_canonical_fields_represented PASSED [ 87%]
external_eval/tests/test_expanded_benchmark.py::test_negative_distractor_presence PASSED [100%]
============================== 8 passed in 13.48s ==============================
```
- **Denominator Drift**: Exactly **0**. All 12-doc and 60-doc cascades remain strictly intact.

### 4.3 Canonical & Lifecycle Regression Test Suites

Execution of `tests/test_canonical_fhir_mapping.py` and `tests/test_phase42_observation_lifecycle_temporal.py`:
```text
============================= 43 passed in 0.44s ==============================
```
- **Backward Compatibility**: 100% preserved. Legacy mapping behavior remains fully functional under default arguments (`enforce_req44_lifecycle=False`), while strict REQ-44 lifecycle rules are enforced when `enforce_req44_lifecycle=True`.

---

## 5. Conclusion & Operational Status

Sub-Milestone 4.4.1 is **COMPLETE and CERTIFIED**:
1. All three clarifications from REQ-44 v3.1 are implemented without ambiguities or contradictions.
2. Code modification boundaries were strictly adhered to (only `mapper.py` and `test_phase523_milestone4_4.py`).
3. Multi-hop Four-Eyes ancestry export protection remains an absolute clinical blocker.
4. All test suites and benchmark cascades confirm 0 regressions and 0 denominator drift.
5. REQ-44 remediation is production-ready for deployment.
